Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interstitial Infusion of IL 13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
NCT00006268Phase 2Completed
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
- Start
- Oct 2000
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cintredekin besudotox in malignant glioma, sponsored by New Approaches to Brain Tumor Therapy Consortium. Primary endpoints: Maximum Tolerated Dose, Dose-Limiting Toxicity and 5 more. Started Oct 2000; status: completed.
02
Drugs
cintredekin besudotox
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00006268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006268.